Treatment outcomes following continuous miglustat therapy in
Por um escritor misterioso
Last updated 16 junho 2024
![Treatment outcomes following continuous miglustat therapy in](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2Fs13023-020-01363-2/MediaObjects/13023_2020_1363_Fig1_HTML.png)
Background Niemann-Pick disease Type C (NP-C) is a rare, progressive neurodegenerative disorder characterized by progressive neurodegeneration and premature death. We report data at closure of the NPC Registry that describes the natural history, disease course and treatment experience of NP-C patients in a real-world setting. Methods The NPC Registry was a prospective observational cohort study that ran between September 2009 and October 2017. Patients with a confirmed diagnosis of NP-C were enrolled regardless of treatment status. All patients underwent clinical assessments and medical care as determined by their physicians; data were collected through a secure internet-based portal. Results At closure on October 19, 2017, 472 patients from 22 countries were enrolled in the NPC Registry. Mean (standard deviation) age at enrollment was 21.2 (15.0) years, and 51.9% of patients were male. First neurological symptom onset occurred during the early-infantile (< 2 years), late-infantile (2 to < 6 years), juvenile (6 to < 15 years), or adolescent/adult (≥ 15 years) periods in 13.5, 25.6, 31.8, and 29.1% of cases, respectively. The most frequent neurological manifestations prior to enrollment included ataxia (67.9%), vertical supranuclear gaze palsy (67.4%), dysarthria (64.7%), cognitive impairment (62.7%), dysphagia (49.1%), and dystonia (40.2%). During infancy, splenomegaly and hepatomegaly were frequent (n = 199/398 [50%] and n = 147/397 [37.0%], respectively) and persisted in most affected patients. Of the 472 enrolled patients, 241 were continuously treated with miglustat during the NPC Registry observation period, of whom 172 of these 241 patients were treated continuously for ≥12 months. A composite disability score that assesses impairment of ambulation, manipulation, language, and swallowing was highest in the early-infantile population and lowest in the adolescent/adult population. Among the continuous miglustat therapy population, 70.5% of patients had improved or had stable disease (at least 3 of the 4 domains having a decreased or unchanged score between enrollment and last follow-up). The NPC Registry did not identify any new safety signals associated with miglustat therapy. Conclusions The profiles of clinical manifestations in the final NPC Registry dataset agreed with previous clinical descriptions. Miglustat therapy was associated with a stabilization of neurological manifestations in most patients. The safety and tolerability of miglustat therapy was consistent with previous reports.
![Treatment outcomes following continuous miglustat therapy in](https://thejns.org/focus/cover/journals/neurosurg-focus/24/3-4/cover.jpg)
Central nervous system therapy for lysosomal storage disorders in
![Treatment outcomes following continuous miglustat therapy in](https://pub.mdpi-res.com/jcm/jcm-12-03269/article_deploy/html/images/jcm-12-03269-g001.png?1683183569)
JCM, Free Full-Text
![Treatment outcomes following continuous miglustat therapy in](https://pubs.acs.org/cms/10.1021/mp200313e/asset/images/medium/mp-2011-00313e_0006.gif)
Therapeutic Strategies for Gaucher Disease: Miglustat (NB-DNJ) as
![Treatment outcomes following continuous miglustat therapy in](https://jpet.aspetjournals.org/content/jpet/387/2/188/F8.large.jpg)
Increasing Enzyme Mannose-6-Phosphate Levels but Not Miglustat
![Treatment outcomes following continuous miglustat therapy in](https://journals.sagepub.com/cms/10.1177/0883073812464526/asset/images/large/10.1177_0883073812464526-fig1.jpeg)
Effects of Miglustat on Stabilization of Neurological Disorder in
![Treatment outcomes following continuous miglustat therapy in](https://og.oa.mg/Miglustat%20Improves%20Purkinje%20Cell%20Survival%20and%20Alters%20Microglial%20Phenotype%20in%20Feline%20Niemann-Pick%20Disease%20Type%20C.png?author=%20Veronika%20M.%20Stein,%20Alexandra%20Crooks,%20Wenge%20Ding,%20Maria%20Prociuk,%20Patricia%20O'Donnell,%20Caroline%20Bryan,%20Tracey%20Sikora,%20Jasper%20Dingemanse,%20Marie%20T.%20Vanier,%20Steven%20U.%20Walkley,%20Charles%20H.%20Vite)
PDF] Miglustat Improves Purkinje Cell Survival and Alters
![Treatment outcomes following continuous miglustat therapy in](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-022-06112-y/MediaObjects/41598_2022_6112_Fig1_HTML.png)
Correlation of age of onset and clinical severity in Niemann–Pick
![Treatment outcomes following continuous miglustat therapy in](https://onlinelibrary.wiley.com/cms/asset/b3d81e5b-ccdc-44ba-bc88-300f6760a977/ntbl003.jpg)
Randomized, controlled trial of miglustat in Gaucher's disease
![Treatment outcomes following continuous miglustat therapy in](https://www.neurology.org/cms/10.1212/WNL.0000000000008441/asset/41d2648d-a967-406e-adf2-adca769c01d9/assets/graphic/5ff1.jpeg)
Large variation in effects during 10 years of enzyme therapy in
![Treatment outcomes following continuous miglustat therapy in](https://www.researchgate.net/profile/Mercedes-Pineda/publication/277411428/figure/fig2/AS:294436199256074@1447210468813/Proportions-of-patients-who-received-continuous-miglustat-therapy-during-follow-up-and_Q320.jpg)
Proportions of patients who received continuous miglustat therapy
![Treatment outcomes following continuous miglustat therapy in](https://d3i71xaburhd42.cloudfront.net/903403ed7f2ca16be5230ab0ced49505dc4bf967/3-Table1-1.png)
PDF] Miglustat for treatment of Niemann-Pick C disease: a
![Treatment outcomes following continuous miglustat therapy in](https://www.thelancet.com/cms/attachment/79223918-ea86-4a35-9854-f40aae5b4f17/gr1_lrg.gif)
Eliglustat compared with imiglucerase in patients with Gaucher's
![Treatment outcomes following continuous miglustat therapy in](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs00415-023-12096-0/MediaObjects/415_2023_12096_Fig1_HTML.png)
Long-term safety and efficacy of cipaglucosidase alfa plus
![Treatment outcomes following continuous miglustat therapy in](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs00415-021-10717-0/MediaObjects/415_2021_10717_Fig1_HTML.png)
Efficacy and safety of N-acetyl-l-leucine in Niemann–Pick disease
![Treatment outcomes following continuous miglustat therapy in](https://www.frontiersin.org/files/Articles/457933/fmicb-10-00962-HTML/image_m/fmicb-10-00962-g001.jpg)
Frontiers Immunometabolism and Pulmonary Infections
Recomendado para você
-
Niemann-Pick disease type C: Video & Anatomy16 junho 2024
-
IJMS, Free Full-Text16 junho 2024
-
NNPDF on X: October is Global Niemann-Pick Disease Awareness Month! For more information on Niemann-Pick Disease or to make a donation to NNPDF go to #niemannpick #ASMD #NPC #raredisease #NNPDF #NiemannPickC16 junho 2024
-
Niemann-Pick disease Information16 junho 2024
-
NNPDF on X: October is Global Niemann-Pick Disease Awareness16 junho 2024
-
National Niemann-Pick Disease Foundation, Inc. - October is Global16 junho 2024
-
University College London begins preclinical studies to develop a16 junho 2024
-
Hepatocellular carcinoma as a complication of Niemann‐Pick disease16 junho 2024
-
Frontiers Lysosomal and Mitochondrial Liaisons in Niemann-Pick16 junho 2024
-
Construction of Niemann Pick Disease Type C1 HEK293 Cell Model16 junho 2024
você pode gostar
-
História e Regras do FUTSAL16 junho 2024
-
MM2 SONG CODES/ID'S #8 - in 202316 junho 2024
-
maxdubrinsky (Max Dubrinsky) · GitHub16 junho 2024
-
Linda garota de desenho animado com vetor premium de ilustração de bolo16 junho 2024
-
Does no one on this subreddit remember the *canon* Sonic.EXE anymore? : r/ SonicEXE16 junho 2024
-
Man of Steel #1 (1986) - Chris is on Infinite Earths16 junho 2024
-
One Piece é a 8ª série mais assistida da Netflix ao redor do mundo16 junho 2024
-
Kazuya Mishima in Tekken 8, get ready! : r/Tekken16 junho 2024
-
One Night at Flumpty's by Xamp6 on DeviantArt Игровые арты, Милые рисунки, Фан арт16 junho 2024
-
mascaras do roblox16 junho 2024